| Evolent Pathways | Febrile Neutropenic Risk | Emetogenic Risk | References | ||
|---|---|---|---|---|---|
| INDUCTION | |||||
Low/Intermediate risk |
ATRA (all-trans-retinoic acid) and arsenic trioxide |
Low | Moderate |
|
|
High Risk |
ATRA (all-trans-retinoic acid), arsenic trioxide and daunorubicin |
Low | Moderate |
|
|
ATRA (all-trans-retinoic acid), arsenic trioxide and idarubicin |
Low | Moderate |
|
||
| RELAPSE/REFRACTORY | |||||
arsenic trioxide |
Low | Moderate |
|
||
arsenic trioxide and ATRA (all-trans-retinoic acid) |
Low | Moderate |
|
||
ATRA (all-trans-retinoic acid), arsenic trioxide and daunorubicin *if anthracycline naïve* |
Low | Moderate |
|
||
ATRA (all-trans-retinoic acid), arsenic trioxide and idarubicin *if anthracycline naïve* |
Low | Moderate |
|
||
ATRA (all-trans-retinoic acid), arsenic trioxide *if prior anthracycline* |
Low | Moderate |
|
||
Best Supportive Care or Clinical Trial |
|
||||
Low/Intermediate risk
ATRA (all-trans-retinoic acid) and arsenic trioxide
High Risk
ATRA (all-trans-retinoic acid), arsenic trioxide and daunorubicin
ATRA (all-trans-retinoic acid), arsenic trioxide and idarubicin
arsenic trioxide
arsenic trioxide and ATRA (all-trans-retinoic acid)
ATRA (all-trans-retinoic acid), arsenic trioxide and daunorubicin *if anthracycline naïve*
ATRA (all-trans-retinoic acid), arsenic trioxide and idarubicin *if anthracycline naïve*
ATRA (all-trans-retinoic acid), arsenic trioxide *if prior anthracycline*
Best Supportive Care or Clinical Trial